{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T11:27:12Z","timestamp":1789298832089,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    In the present work, a new series of 14 novel phthalimide-benzenesulfonamide derivatives\n                    <jats:bold>4a<\/jats:bold>\n                    \u2013\n                    <jats:bold>n<\/jats:bold>\n                    were synthesized, and their inhibitory activity against yeast \u03b1-glucosidase was screened. The obtained results indicated that most of the newly synthesized compounds showed prominent inhibitory activity against \u03b1-glucosidase. Among them, 4-phenylpiperazin derivative\n                    <jats:bold>4m<\/jats:bold>\n                    exhibited the strongest inhibition with the IC\n                    <jats:sub>50<\/jats:sub>\n                    value of 52.2\u2009\u00b1\u20090.1\u00a0\u00b5M. Enzyme kinetic study of compound\n                    <jats:bold>4m<\/jats:bold>\n                    proved that its inhibition mode was competitive and K\n                    <jats:sub>i<\/jats:sub>\n                    value of this compound was calculated to be 52.7\u00a0\u00b5M. In silico induced fit docking and molecular dynamics studies were performed to further investigate the interaction, orientation, and conformation of the target compounds over the active site of \u03b1-glucosidase. Obtained date of these studies demonstrated that our new compounds interacted as well with the \u03b1-glucosidase active site with the acceptable binding energies. Furthermore, in silico druglikeness\/ADME\/Toxicity studies of compound\n                    <jats:bold>4m<\/jats:bold>\n                    were performed and predicted that this compound is druglikeness and has good ADME and toxicity profiles.\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-14896-2","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T12:37:07Z","timestamp":1655901427000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Design, synthesis, in vitro \u03b1-glucosidase inhibition, docking, and molecular dynamics of new phthalimide-benzenesulfonamide hybrids for targeting type 2 diabetes"],"prefix":"10.1038","volume":"12","author":[{"given":"Mohammad","family":"Askarzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Homa","family":"Azizian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Adib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Mohammadi-Khanaposhtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somayeh","family":"Mojtabavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ali","family":"Faramarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed Mahmoud","family":"Sajjadi-Jazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bagher","family":"Larijani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haleh","family":"Hamedifar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Mahdavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"14896_CR1","first-page":"49","volume":"5","author":"O Gheith","year":"2016","unstructured":"Gheith, O. et al. Diabetic kidney disease: World wide difference of prevalence and risk factors. J. Nephropharmacol. 5, 49 (2016).","journal-title":"J. Nephropharmacol."},{"key":"14896_CR2","first-page":"1","volume":"5","author":"MN Piero","year":"2015","unstructured":"Piero, M. N. et al. Diabetes mellitus\u2014A devastating metabolic disorder. Asian J. Biomed. Pharm. Sci. 5, 1 (2015).","journal-title":"Asian J. Biomed. Pharm. Sci."},{"key":"14896_CR3","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1055\/a-0584-6223","volume":"126","author":"A Petersmann","year":"2018","unstructured":"Petersmann, A. et al. Definition, classification and diagnosis of diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 126, 406\u2013410 (2018).","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"14896_CR4","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.2337\/db10-1032","volume":"59","author":"RA Rizza","year":"2010","unstructured":"Rizza, R. A. Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: Implications for therapy. Diabetes 59, 2697\u20132707. https:\/\/doi.org\/10.2337\/db10-1032 (2010).","journal-title":"Diabetes"},{"key":"14896_CR5","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s40279-018-0864-x","volume":"48","author":"A Borror","year":"2018","unstructured":"Borror, A. et al. The effects of postprandial exercise on glucose control in individuals with type 2 diabetes: A systematic review. Sports Med. 48, 1479\u20131491. https:\/\/doi.org\/10.1007\/s40279-018-0864-x (2018).","journal-title":"Sports Med."},{"key":"14896_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1086\/682587","volume":"90","author":"K Hardy","year":"2015","unstructured":"Hardy, K. et al. The importance of dietary carbohydrate in human evolution. Rev. Biol. 90, 251\u2013268. https:\/\/doi.org\/10.1086\/682587 (2015).","journal-title":"Rev. Biol."},{"key":"14896_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2174\/138955710791331007","volume":"10","author":"R Tundis","year":"2010","unstructured":"Tundis, R. et al. Natural products as \u03b1-amylase and \u03b1-glucosidase inhibitors and their hypoglycaemic potential in the treatment of diabetes: An update. Mini Rev. Med. Chem. 10, 315\u2013331. https:\/\/doi.org\/10.2174\/138955710791331007 (2010).","journal-title":"Mini Rev. Med. Chem."},{"key":"14896_CR8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/B978-0-12-813822-9.00036-9","volume-title":"Bioactive Food as Dietary Interventions for Diabetes","author":"Y Dong","year":"2019","unstructured":"Dong, Y. et al. Intervention of Prediabetes by Flavonoids from Oroxylum indicum. In Bioactive Food as Dietary Interventions for Diabetes (eds Watson, R. & Preedy, V.) 559\u2013575 (Academic Press, 2019). https:\/\/doi.org\/10.1016\/B978-0-12-813822-9.00036-9."},{"key":"14896_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/8904-2014-345","volume":"18","author":"Y Shimada","year":"2015","unstructured":"Shimada, Y. et al. Proteasome inhibitor bortezomib enhances the activity of multiple mutant forms of lysosomal a glucosidase in Pompe disease. JIMD Rep. 18, 33\u201339. https:\/\/doi.org\/10.1007\/8904-2014-345 (2015).","journal-title":"JIMD Rep."},{"key":"14896_CR10","first-page":"2920","volume":"55","author":"R Pili","year":"1995","unstructured":"Pili, R. et al. The aglucosidase I inhibitor castanospermine alters endothelial cell glycosylation, prevents angiogenesis, and inhibits tumor growth. Cancer Res. 55, 2920\u20132926 (1995).","journal-title":"Cancer Res."},{"issue":"482","key":"14896_CR11","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.3390\/ph14050482","volume":"14","author":"SA Halim","year":"2021","unstructured":"Halim, S. A. et al. Rational design of novel inhibitors of \u03b1-glucosidase: An application of quantitative structure activity relationship and structure-based virtual screening. Pharmaceuticals 14(482), 2021. https:\/\/doi.org\/10.3390\/ph14050482 (2021).","journal-title":"Pharmaceuticals"},{"key":"14896_CR12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.2174\/1570179417666200325124712","volume":"17","author":"ML Almeida","year":"2020","unstructured":"Almeida, M. L. et al. Advances in synthesis and medicinal applications of compounds derived from phthalimide. Curr. Org. Synth. 17, 252\u2013270. https:\/\/doi.org\/10.2174\/1570179417666200325124712 (2020).","journal-title":"Curr. Org. Synth."},{"key":"14896_CR13","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1021\/jm990068t","volume":"43","author":"J Vamecq","year":"2000","unstructured":"Vamecq, J. et al. Synthesis and anticonvulsant and neurotoxic properties of substituted N-phenyl derivatives of the phthalimide pharmacophore. J. Med. Chem. 43, 1311\u20131319. https:\/\/doi.org\/10.1021\/jm990068t (2000).","journal-title":"J. Med. Chem."},{"key":"14896_CR14","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3928204","author":"HS Abdulrahman","year":"2020","unstructured":"Abdulrahman, H. S. et al. Synthesis of phthalimide imine derivatives as a potential anticancer agent. J. Chem. https:\/\/doi.org\/10.1155\/2020\/3928204 (2020).","journal-title":"J. Chem."},{"key":"14896_CR15","doi-asserted-by":"publisher","first-page":"781","DOI":"10.17179\/excli2016-654","volume":"15","author":"HS Rateb","year":"2016","unstructured":"Rateb, H. S. et al. Discovery of novel phthalimide analogs: Synthesis, antimicrobial and antitubercular screening with molecular docking studies. EXCLI J. 15, 781. https:\/\/doi.org\/10.17179\/excli2016-654 (2016).","journal-title":"EXCLI J."},{"key":"14896_CR16","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2020.1871073","author":"VN Holanda","year":"2021","unstructured":"Holanda, V. N. et al. Identification of 1, 2, 3-triazole-phthalimide derivatives as potential drugs against COVID-19: A virtual screening, docking and molecular dynamics study. J. Biomol. Struct. Dyn. https:\/\/doi.org\/10.1080\/07391102.2020.1871073 (2021).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"14896_CR17","first-page":"1581","volume":"23","author":"S Mahapatra","year":"2011","unstructured":"Mahapatra, S. et al. Evaluation of some synthesized novel substituted phthalimide derivatives as potent antidiabetic agents. Asian J. Chem. 23, 1581 (2011).","journal-title":"Asian J. Chem."},{"key":"14896_CR18","doi-asserted-by":"publisher","first-page":"5903","DOI":"10.1016\/j.bmc.2010.06.088","volume":"18","author":"R Pascale","year":"2010","unstructured":"Pascale, R. et al. New N-(phenoxydecyl) phthalimide derivatives displaying potent inhibition activity towards \u03b1-glucosidase. Bioorg. Med. Chem. 18, 5903\u20135914. https:\/\/doi.org\/10.1016\/j.bmc.2010.06.088 (2010).","journal-title":"Bioorg. Med. Chem."},{"key":"14896_CR19","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/j.bmcl.2013.02.011","volume":"23","author":"X Bian","year":"2013","unstructured":"Bian, X. et al. A new series of N2-substituted-5-(p-toluenesulfonylamino) phthalimide analogues as \u03b1-glucosidase inhibitors. Bioorg. Med. Chem. Lett. 23, 2022\u20132026. https:\/\/doi.org\/10.1016\/j.bmcl.2013.02.011 (2013).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"14896_CR20","doi-asserted-by":"publisher","first-page":"4379","DOI":"10.1007\/s11696-020-01246-7","volume":"74","author":"M Sherafati","year":"2020","unstructured":"Sherafati, M. et al. Design, synthesis and biological evaluation of novel phthalimide-Schiff base-coumarin hybrids as potent \u03b1-glucosidase inhibitors. Chem. Pap. 74, 4379\u20134388. https:\/\/doi.org\/10.1007\/s11696-020-01246-7 (2020).","journal-title":"Chem. Pap."},{"key":"14896_CR21","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1016\/j.bmcl.2017.05.007","volume":"27","author":"G Wang","year":"2017","unstructured":"Wang, G. et al. Synthesis, biological evaluation and molecular docking studies of chromone hydrazone derivatives as \u03b1-glucosidase inhibitors. Bioorg. Med. Chem. Lett. 27, 2957\u20132961. https:\/\/doi.org\/10.1016\/j.bmcl.2017.05.007 (2017).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"14896_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.103491","volume":"94","author":"A Aispuro-P\u00e9rez","year":"2020","unstructured":"Aispuro-P\u00e9rez, A. et al. Synthesis and molecular docking studies of imines as \u03b1-glucosidase and \u03b1-amylase inhibitors. Bioorg. Chem. 94, 103491. https:\/\/doi.org\/10.1016\/j.bioorg.2019.103491 (2020).","journal-title":"Bioorg. Chem."},{"key":"14896_CR23","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.1111\/j.1742-4658.2010.07810.x","volume":"277","author":"K Yamamoto","year":"2010","unstructured":"Yamamoto, K. et al. Crystal structures of isomaltase from Saccharomyces cerevisiae and in complex with its competitive inhibitor maltose. FEBS J. 277, 4205\u20134214. https:\/\/doi.org\/10.1111\/j.1742-4658.2010.07810.x (2010).","journal-title":"FEBS J."},{"key":"14896_CR24","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1042\/bj3210557","volume":"321","author":"GJ Davies","year":"1997","unstructured":"Davies, G. J. et al. Nomenclature for sugar-binding subsites in glycosyl hydrolases. Biochem. J. 321, 557. https:\/\/doi.org\/10.1042\/bj3210557 (1997).","journal-title":"Biochem. J."},{"key":"14896_CR25","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1006\/jmbi.1998.1992","volume":"281","author":"Y Katsuya","year":"1998","unstructured":"Katsuya, Y. et al. Three-dimensional structure of Pseudomonas isoamylase at 2.2 \u00c5 resolution. J. Mol. Biol. 281, 885\u2013897. https:\/\/doi.org\/10.1006\/jmbi.1998.1992 (1998).","journal-title":"J. Mol. Biol."},{"key":"14896_CR26","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jbiosc.2011.08.016","volume":"112","author":"K Yamamoto","year":"2011","unstructured":"Yamamoto, K. et al. Steric hindrance by 2 amino acid residues determines the substrate specificity of isomaltase from Saccharomyces cerevisiae. J. Biosci. Bioeng. 112, 545\u2013550. https:\/\/doi.org\/10.1016\/j.jbiosc.2011.08.016 (2011).","journal-title":"J. Biosci. Bioeng."},{"key":"14896_CR27","unstructured":"Bioinformatics and Molecular Design Research Center. Pre-ADMET program. Bioinformatics and Molecular Design Research Center, Seoul, South Korea. http:\/\/preadmet.bmdrc.org (2014)."},{"key":"14896_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.103206","volume":"92","author":"MS Asgari","year":"2019","unstructured":"Asgari, M. S. et al. Biscoumarin-1, 2, 3-triazole hybrids as novel anti-diabetic agents: Design, synthesis, in vitro \u03b1-glucosidase inhibition, kinetic, and docking studies. Bioorg. Chem. 92, 103206. https:\/\/doi.org\/10.1016\/j.bioorg.2019.103206 (2019).","journal-title":"Bioorg. Chem."},{"key":"14896_CR29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/17415993.2013.801476","volume":"35","author":"A Kiani","year":"2014","unstructured":"Kiani, A. et al. Direct synthesis of sulfonyl azides from sulfonic acids. J. Sulphur Chem. 35, 119\u2013127. https:\/\/doi.org\/10.1080\/17415993.2013.801476 (2014).","journal-title":"J. Sulphur Chem."},{"key":"14896_CR30","unstructured":"Schr\u00f6dinger Suite 2018, Induced Fit Docking protocol; Glide Version 5.5, S., LLC, New York, NY, 2009; Prime Version 2.1, Schr\u00f6dinger, LLC, New York, NY, 2009."},{"key":"14896_CR31","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.ijbiomac.2020.10.263","volume":"166","author":"F Azimi","year":"2021","unstructured":"Azimi, F. et al. Design and synthesis of novel pyrazole-phenyl semicarbazone derivatives as potential \u03b1-glucosidase inhibitor: Kinetics and molecular dynamics simulation study. Int. J. Biol. Macromol. 166, 1082\u20131095. https:\/\/doi.org\/10.1016\/j.ijbiomac.2020.10.263 (2021).","journal-title":"Int. J. Biol. Macromol."},{"key":"14896_CR32","unstructured":"ChemAxon Marvin was used for drawing, displaying and characterizing Chemical structures, substructures and reactions, Marvin 15.10.12.0 (version number), ChemAxon http:\/\/www.chemaxon.com (2015)."},{"key":"14896_CR33","unstructured":"Schr\u00f6dinger Release 2018-4: Schr\u00f6dinger Release 2018-4 Protein Preparation Wizard; Epik, Schr\u00f6dinger, LLC, New York, NY, 2016; Impact, Schr\u00f6dinger, LLC, New York, NY, 2016; Prime, Schr\u00f6dinger, LLC, New York, NY, 2019."},{"key":"14896_CR34","volume-title":"Schr\u00f6dinger Release 2018-4: LigPrep","author":"Schr\u00f6dinger LLC","year":"2018","unstructured":"Schr\u00f6dinger LLC. Schr\u00f6dinger Release 2018-4: LigPrep (Schr\u00f6dinger LLC, 2018)."},{"key":"14896_CR35","unstructured":"Schr\u00f6dinger Release 2018-4: Induced Fit Docking Protocol; Glide, Schr\u00f6dinger, LLC, New York, NY, 2018; Prime, Schr\u00f6dinger, LLC, New York, NY, 2018."},{"key":"14896_CR36","volume-title":"Schr\u00f6dinger Release 2018-4: Desmond Molecular Dynamics System, D. E. Shaw Research, New York, NY, 2018. Maestro-Desmond Interoperability Tools","author":"Schr\u00f6dinger LLC","year":"2018","unstructured":"Schr\u00f6dinger LLC. Schr\u00f6dinger Release 2018-4: Desmond Molecular Dynamics System, D. E. Shaw Research, New York, NY, 2018. Maestro-Desmond Interoperability Tools (Schr\u00f6dinger LLC, 2018)."},{"key":"14896_CR37","doi-asserted-by":"publisher","first-page":"896","DOI":"10.3390\/ph14090896","volume":"14","author":"SA Halim","year":"2021","unstructured":"Halim, S. A. Main protease through structure-based virtual screening and molecular dynamic simulation. Pharmaceuticals 14, 896. https:\/\/doi.org\/10.3390\/ph14090896 (2021).","journal-title":"Pharmaceuticals"},{"key":"14896_CR38","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ejmech.2018.09.057","volume":"159","author":"I Pibiri","year":"2018","unstructured":"Pibiri, I. et al. Rescuing the CFTR protein function: Introducing 1,3,4-oxadiazoles as translational readthrough inducing drugs. Eur. J. Med. Chem. 159, 126\u2013142. https:\/\/doi.org\/10.1016\/j.ejmech.2018.09.057 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"14896_CR39","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3390\/computation8030077","volume":"8","author":"G Culletta","year":"2020","unstructured":"Culletta, G. et al. Exploring the SARS-CoV-2 proteome in the search of potential inhibitors via structure-based pharmacophore modeling\/docking approach. Computation 8, 77. https:\/\/doi.org\/10.3390\/computation8030077 (2020).","journal-title":"Computation"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14896-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14896-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14896-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:47:59Z","timestamp":1669337279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14896-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["14896"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-14896-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,22]]},"assertion":[{"value":"3 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10569"}}